TScan Therapeutics (TCRX) Accumulated Expenses (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Accumulated Expenses data on file, last reported at $8.6 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 324.51% year-over-year to $8.6 million in Q1 2026; TTM through Mar 2026 was $8.6 million, a 324.51% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, down 73.1% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $8.6 million, up from $4.1 million in the prior quarter.
• Over the last five years, Accumulated Expenses for TCRX reached as high as $15.4 million in Q4 2024 and fell as low as $1.0 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $6.9 million across 5 years, with a median of $5.5 million in 2023.
• Across the five-year window, Accumulated Expenses jumped 643.06% in 2023 and sank 76.96% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $4.4 million in 2022, then rose by 25.73% to $5.5 million in 2023, then soared by 181.31% to $15.4 million in 2024, then sank by 73.1% to $4.1 million in 2025, then jumped by 107.29% to $8.6 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $8.6 million in Q1 2026, $4.1 million in Q4 2025, and $10.8 million in Q3 2025.